Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)

Number of Participants Who Experienced an Adverse Event

Participants who experienced treatment-emergent adverse events, defined as newly reported events after baseline or events reported to have worsened in severity since baseline (from the date of informed consent to the last dose day + 7 days for non-serious adverse events and 30 days for serious adverse events).

Time frame: Up to Day 42 (treatment period)

Number of Participants Who Discontinued Because of an Adverse Event

Discontinuations due to treatment-emergent adverse events starting on or after Day1 and up to 7 days after study medication stop date (30 days for serious adverse events).

Time frame: up to 30 days after study medication stop date

Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, Tmax

Tmax defined as time to peak concentration.

Time frame: Day 4 or 8

Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis,Cmax

Cmax defined as peak concentration.

Time frame: Day 4 or 8

Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis , Dn-Cmax

dn-Cmax is defined as dose normalized peak concentration.

Time frame: Day 4 or 8

Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, Cmin

Cmin defined as pre-dose concentration.

Time frame: Day 4 or 8

Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, AUC 0-12

AUC 0-12 defined as area-under-the-curve from zero to time point 12 hours.